respectively. The most common injection site reactions wereerythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in REPATHA-treated patients and placebo-treated patients were 0.1% and 0%, respectively. ...
Repatha(evolocumab) 使用说明书 用于降低低密度脂蛋白(LDL)胆固醇 英文版 HAOEYOU(好医友) BLA125522tofirm0827 HIGHLIGHTSOFPRESCRIBINGINFORMATION Thesehighlightsdonotincludealltheinformationneededtouse REPATHA™safelyandeffectively.Seefullprescribinginformationfor REPATHA. REPATHA(evolocumab)injection,forsubcutaneous...
57个抗体药物说明书repatha.pdf,BLA 125522 to firm 08 27 HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS These highlights do not include all the information needed to use • Injection: 140 mg/mL in a single-use prefilled syringe (3)